Cargando…

Voclosporin: Unique Chemistry, Pharmacology and Toxicity Profile, and Possible Options for Implementation into the Management of Lupus Nephritis

Calcineurin inhibitors (CNI) can suppress allo- and autoimmunity by suppressing T cell function but also have anti-proteinuric effects by stabilizing the cellular components of the kidney’s filtration barrier. Therefore, CNI are used in autoimmune kidney diseases with proteinuria. However, the tradi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kale, Ajinath, Shelke, Vishwadeep, Lei, Yutian, Gaikwad, Anil Bhanudas, Anders, Hans-Joachim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605893/ https://www.ncbi.nlm.nih.gov/pubmed/37887284 http://dx.doi.org/10.3390/cells12202440

Ejemplares similares

How to use COVID-19 antiviral drugs in patients with chronic kidney disease
por: Kale, Ajinath, et al.
Publicado: (2023)

Voclosporin for Lupus Nephritis: A #NephJC Editorial on AURORA
por: Auguste, Bourne, et al.
Publicado: (2021)

Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis
por: Baum, Rebecca, et al.
Publicado: (2023)

168 Victory With Voclosporin: A Case of Complete Remission in Severe Lupus Nephritis
Publicado: (2023)

25 Efficacy of Voclosporin Across Lupus Nephritis Biopsy Classes: Pooled Data From the AURORA and AURA-LV Trials
Publicado: (2021)

Voclosporin: First Approval
por: Heo, Young-A
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Voclosporin
por: Abdel-Kahaar, Emaad, et al.
Publicado: (2023)

Voclosporin as a Treatment for Noninfectious Uveitis
por: Schultz, Clyde
Publicado: (2013)

The effectiveness and value of belimumab and voclosporin for lupus nephritis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2021)

Kidney disease in lupus is not always 'lupus nephritis'
por: Anders, Hans-Joachim, et al.
Publicado: (2013)

Journal Club: Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Double‐Blind, Randomized, Multicenter, Placebo‐Controlled, Phase 3 Trial
por: Rubio, Jose, et al.
Publicado: (2021)

Toll-like receptors in lupus nephritis
por: Devarapu, Satish Kumar, et al.
Publicado: (2018)

Understanding lupus nephritis: diagnosis, management, and treatment options
por: Mok, Chi Chiu
Publicado: (2012)

SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus
por: Smith, Michael A., et al.
Publicado: (2019)

Lupus Nephritis: Current Perspectives and Moving Forward
por: Lichtnekert, Julia, et al.
Publicado: (2022)

Hydration-Induced Phase Separation in Amphiphilic Polymer Matrices and its Influence on Voclosporin Release
por: Khan, I. John, et al.
Publicado: (2012)

Identification of Unique MicroRNA Signature Associated with Lupus Nephritis
por: Te, Jeannie L., et al.
Publicado: (2010)

Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis
por: Roesel, Martin, et al.
Publicado: (2011)

Protective effect of the novel calcineurin inhibitor voclosporin in experimental colitis
por: Lindemann, Aylin, et al.
Publicado: (2023)

Differential Effects of Voclosporin and Tacrolimus on Insulin Secretion From Human Islets
por: Kolic, Jelena, et al.
Publicado: (2020)

A Unique Case of Membranous Lupus Nephritis Identified After Pronase Digestion
por: Kannan, Lakshmi
Publicado: (2022)

Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials
por: Steiger, Stefanie, et al.
Publicado: (2022)

Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE
por: van Gelder, Teun, et al.
Publicado: (2021)

The Pathogenesis of Lupus Nephritis
por: Sterner, Rosalie M., et al.
Publicado: (2014)

Pediatric lupus nephritis
por: Pinheiro, Sergio Veloso Brant, et al.
Publicado: (2018)

Hyperhomocysteinemia and Lupus Nephritis
por: Timlin, Homa, et al.
Publicado: (2019)

Management of Lupus Nephritis
por: Tamirou, Farah, et al.
Publicado: (2021)

Lupus Nephritis and Dysbiosis
por: Monticolo, Marta, et al.
Publicado: (2023)

Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine
por: Anders, Hans-Joachim, et al.
Publicado: (2015)

Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis
por: Kwon, Oh Chan, et al.
Publicado: (2020)

Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin)
por: Kuglstatter, Andreas, et al.
Publicado: (2011)

Molecular mechanism of Hedyotis Diffusae Herba in the treatment of lupus nephritis based on network pharmacology
por: Yang, Jinfei, et al.
Publicado: (2023)

Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis
por: Tveita, Anders, et al.
Publicado: (2008)

Lupus nephritis: current update
por: Saxena, Ramesh, et al.
Publicado: (2011)

The Role of Cytokine in the Lupus Nephritis
por: Iwata, Yasunori, et al.
Publicado: (2011)

Chapter 12: Lupus nephritis
Publicado: (2012)

Biomarker Profiling for Lupus Nephritis
por: Li, Yajuan, et al.
Publicado: (2013)

The Role of Autophagy in Lupus Nephritis
por: Wang, Linlin, et al.
Publicado: (2015)

Current status of lupus nephritis
por: Jaryal, Ajay, et al.
Publicado: (2017)

Antiphospholipid Antibodies in Lupus Nephritis
por: Parodis, Ioannis, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7b247gu3i30akhangaels8fivv